1. Vlasakakis G, Comets E, Keunecke A, Gueorguieva I, Magni P, Terranova N, et al. White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. CPT: Pharmacometrics Syst Pharmacol. 2013;2:e40.
2. Lee JY, Garnett CE, Gobburu JV, Bhattaram VA, Brar S, Earp JC, et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet. 2011;50(10):627–35.
3. Manolis E, Rohou S, Hemmings R, Salmonson T, Karlsson M, Milligan PA. The role of modeling and simulation in development and registration of medicinal products: output from the EFPIA/EMA modeling and simulation workshop. CPT: Pharmacometrics Syst Pharmacol. 2013;2:e31.
4. Kandala B, Hochhaus G. Pharmacometrics in pulmonary diseases. In: Schmidt S, Derendorf H, editors. Applied Pharmacometrics. 1st ed. Springer; 2014. p. 349–82.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014.